发明名称 METHODS FOR PREVENTING OR TREATING CERTAIN DISORDERS BY INHIBITING BINDING OF IL-4 AND/OR IL-13 TO THEIR RESPECTIVE RECEPTORS
摘要 The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
申请公布号 US2017112900(A1) 申请公布日期 2017.04.27
申请号 US201615367680 申请日期 2016.12.02
申请人 Pieris Pharmaceuticals GmbH 发明人 HOHLBAUM ANDREAS;Audoly Laurent;Koller Beverly
分类号 A61K38/17;A61K9/00;A61K9/08 主分类号 A61K38/17
代理机构 代理人
主权项 1. A method of treating or ameliorating a lung disorder that is related to the immune system, comprising administering to a subject in need thereof a human tear lipocalin mutein or a fragment or variant thereof or a fusion protein or conjugate thereof, capable of inhibiting IL-4 and/or IL-13 from binding to their respective receptors, wherein said lipocalin mutein is capable of exhibiting in vivo therapeutic activity in the subject, wherein said lipocalin mutein has a mutated amino acid at any one or more amino acids positions corresponding to position(s) 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1), and wherein said lipocalin mutein has at least 75% identity to the sequence of mature human tear lipocalin (SEQ ID NO: 1).
地址 Freising-Weihenstephan DE
您可能感兴趣的专利